Our study has identified a novel therapeutic strategy based on LIMD1 status, which exploits the loss of this tumour suppressor, offering the potential for targeted treatment for this large cancer-patient population and significantly reduce disease burden worldwide. This evidence concerns the gene LIMD1 and neoplasm.